|
Oops, Our Data Weren't That Good
DailyFinance By Brian Orelli, The Motley Fool Targacept (NAS: TRGT) was a little off target with its initial analysis that its phase 2 trial testing TC-6987 in asthma passed both its co-primary endpoints. It's kind of like being off with earnings estimates, … Targacept reports error in asthma study UPDATE Targacept loses big shareholder, finds error in previous study |
View full post on asthma – Google News